OpenAI to Preview GPT-6 Cyber AI Model for Cybersecurity 
3 clinical-grade skincare creams you really shouldn’t buy online 
Mercedes-Benz Eyes €800 Million Labor Cost Cuts in Germany 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Oracle Shares Fall as New Mexico AI Data Center Faces Power Delays 
SMBC Eyes 20% VPBank Stake in Vietnam Expansion 
Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks 
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 
US Backs Musk in Fight Against EU’s €120 Million X Fine 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Meta Connect Spotlights Camera-Free Smart Glasses Amid Privacy Concerns 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
FDA Weighs Safety Standards for Psychedelic Therapies 
JPMorgan Names Lavatelli Japan Chief in Leadership Shake-Up 
Add as a preferred source on Google
AstraZeneca’s experimental pill camizestrant significantly reduced the risk of disease progression or death in hormone receptor-positive, HER2-negative breast cancer, according to new data presented at the American Society of Clinical Oncology (ASCO) meeting. In the trial, patients switched to camizestrant after early signs of resistance detected through a blood-based liquid biopsy showed a 56% improvement in progression-free survival compared to standard therapy.
This marks the first time liquid biopsy has been used to guide treatment decisions before visible tumor growth. Dr. Eleonora Teplinsky of Valley-Mount Sinai said the early switch approach allows oncologists to “stay ahead of the curve,” potentially changing how breast cancer is treated.
The phase 3 study enrolled 3,256 women with advanced HR-positive, HER2-negative breast cancer. After at least six months of aromatase inhibitors and CDK4/6 inhibitors—like Kisqali (Novartis), Ibrance (Pfizer), or Verzenio (Eli Lilly)—315 patients with ESR1 mutations were identified and randomized. Patients receiving camizestrant plus a CDK4/6 inhibitor saw a median of 16 months without disease progression, versus 9.2 months on standard therapy with placebo.
No new safety issues were reported, and dropout rates remained low. Camizestrant is a selective estrogen receptor degrader (SERD), designed to block estrogen signaling in cancer cells—an alternative when standard hormone therapies lose effectiveness.
In a separate trial, AstraZeneca’s immunotherapy Imfinzi (durvalumab), combined with FLOT chemotherapy, reduced the risk of disease recurrence or death by 29% in early-stage gastric and esophageal cancer patients. The findings support earlier intervention with immunotherapy and are expected to influence global treatment practices.
AstraZeneca CEO Pascal Soriot emphasized the importance of proactive monitoring, calling it the future of cancer care. Both studies were simultaneously published in the New England Journal of Medicine.
